Log in | Register

Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature

G. Umberto Meduri| Lisa Bridges| Mei-Chiung Shih| Paul E. Marik| Reed A. C. Siemieniuk| Mehmet Kocak
Systematic Review
Volume 42, Issue 5 / May , 2016

Pages 829 - 840

Abstract

Purpose

To investigate the effect of prolonged glucocorticoid treatment for patients with acute respiratory distress syndrome (ARDS).

Methods

We conducted two sets of intention-to-treat analyses: (1) a primary analysis of individual patients’ data (IPD) of four randomized controlled trials (RCTs) which investigated methylprednisolone treatment (n = 322) and (2) a trial-level meta-analysis incorporating four additional RCTs which investigated hydrocortisone treatment in early ARDS (n = 297). We standardized definitions to derive outcomes in all datasets. The primary outcome for the IPD analysis was time to achieving unassisted breathing (UAB) by study day 28. Secondary outcomes included mechanical ventilation (MV) and intensive care unit (ICU)-free days, hospital mortality, and time to hospital mortality by day 28.

Results

By study day 28, compared to the placebo group, the methylprednisolone group had fewer patients who died before achieving UAB (12 vs. 29 %; p < 0.001) and more patients who achieved UAB (80 vs. 50 %; p < 0.001). In the methylprednisolone group, time to achieving UAB was shorter [hazard ratio 2.59, 95 % confidence interval (CI) 1.95–3.43; p < 0.001], and hospital mortality was decreased (20 vs. 33 %; p = 0.006), leading to increased MV (13.3 ± 11.8 vs. 7.6 ± 5.7; p < 0.001) and ICU-free days (10.8 ± 0.71 vs. 6.4 ± 0.85; p < 0.001). In those patients randomized before day 14 of ARDS onset, the trial-level meta-analysis indicated decreased hospital mortality (36 vs. 49 %; risk ratio 0.76, 95 % CI 0.59–0.98, I2 = 17 %, p = 0.035; moderate certainty). Treatment was not associated with increased risk for infections (risk ratio 0.77, 95 % CI 0.56–1.08, I2 = 26 %; p = 0.13; moderate certainty).

Conclusions

Prolonged methylprednisolone treatment accelerates the resolution of ARDS, improving a broad spectrum of interrelated clinical outcomes and decreasing hospital mortality and healthcare utilization.

Keywords

References

  1. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE (2009) Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest 136:1631–1643
    • View reference on publisher's website
    • View reference on PubMed
  2. Meduri GU, Eltorky MA (2015) Understanding ARDS-associated fibroproliferation. Intensive Care Med 41:517–520
  3. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (2012) Acute respiratory distress syndrome: the Berlin definition. JAMA 307:2526–2533
  4. Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N, Meade M (2010) Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care 25:420–435
    • View reference on publisher's website
    • View reference on PubMed
  5. Reade MC, Delaney A, Bailey MJ, Harrison DA, Yealy DM, Jones PG, Rowan KM, Bellomo R, Angus DC (2010) Prospective meta-analysis using individual patient data in intensive care medicine. Intensive Care Med 36:11–21
  6. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umbergere R (2007) Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 131:954–963
    • View reference on publisher's website
    • View reference on PubMed
  7. Rezk N, Ibrahim A (2013) Effects of methylprednisolone in early ARDS. Egypt J Chest Dis Tuberc 62:167–172
    • View reference on publisher's website
  8. Meduri GU, Headley S, Golden E, Carson S, Umberger R, Kelso T, Tolley E (1998) Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. A randomized control trial. JAMA 280:159–165
    • View reference on publisher's website
    • View reference on PubMed
  9. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT, Ancukiewicz M (2006) Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354:1671–1684
    • View reference on publisher's website
    • View reference on PubMed
  10. Meduri GU, Marik PE, Chrousos GP, Pastores SM, Arlt W, Beishuizen A, Bokhari F, Zaloga G, Annane D (2008) Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 34:61–69
  11. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171:242–248
    • View reference on publisher's website
    • View reference on PubMed
  12. Annane D, Sébille V, Bellissant E; Ger-Inf-05 Study Group (2006) Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 34(1):22–30
    • View reference on publisher's website
    • View reference on PubMed
  13. Sabry NA, Omar EE-D (2011) Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm 2:73–81
    • View reference on publisher's website
  14. Liu L, Li J, Huang YZ, Liu SQ, Yang CS, Guo FM, Qiu HB, Yang Y (2012) The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency. Zhonghua nei ke za zhi 51:599–603
    • View reference on PubMed
  15. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26:1793–1800
    • View reference on publisher's website
    • View reference on PubMed
  16. Busse J, Guyatt G (2013) Modification of Cochrane tool to assess risk of bias in randomized trials. https://distillercer.com/wp-content/uploads/2014/02/Tool-to-Assess-Risk-of-Bias-in-Randomized-Controlled-Trials.docx
  17. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926
    • View reference on publisher's website
    • View reference on PubMed
  18. Gray J (1998) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154
    • View reference on publisher's website
  19. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509
    • View reference on publisher's website
  20. Therneau T (2000) Modeling survival data: extending the Cox model. Springer, New York
  21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
    • View reference on publisher's website
  22. Tang B, Craig J, Eslick G, Seppelt I, McLean A (2009) Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 37:1594–1603
    • View reference on publisher's website
    • View reference on PubMed
  23. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Group S-S, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schunemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T (2010) Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303:1180–1187
    • View reference on publisher's website
    • View reference on PubMed
  24. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 167:1655–1663
    • View reference on publisher's website
    • View reference on PubMed
  25. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K (1995) Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107:1062–1073
    • View reference on publisher's website
    • View reference on PubMed
  26. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A (1995) Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 108:1303–1314
    • View reference on publisher's website
    • View reference on PubMed
  27. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A (1998) Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 158:1432–1441
    • View reference on publisher's website
    • View reference on PubMed
  28. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP (2005) Nuclear factor-kappaB- and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. NeuroImmunoModulation 12:321–338
    • View reference on publisher's website
    • View reference on PubMed
  29. Meduri GU, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A (1995) Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 108:1315–1325
    • View reference on publisher's website
    • View reference on PubMed
  30. Meduri GU, Tolley EA, Chrousos GP, Stentz F (2002) Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 165:983–991
    • View reference on publisher's website
    • View reference on PubMed
  31. Sinclair SE, Bijoy J, Golden E, Carratu P, Umberger R, Meduri GU (2006) Interleukin-8 and soluble intercellular adhesion molecule-1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment. Minerva Pneumol 45:93–104
  32. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA (2000) Suppression and recovery of adrenal response after short-term, high- dose glucocorticoid treatment. Lancet 355:542–545
    • View reference on publisher's website
    • View reference on PubMed
  33. Pfizer (2009) Solu-medrol. Methylprednisolone sodium succinate product information. Pfizer, New York. Available at:http://labeling.pfizer.com/ShowLabeling.aspx?id=648
  34. Nawab Q, Golden E, Confalonieri M, Umberger R, Meduri G (2011) Corticosteroid treatment in severe community-acquired pneumonia: duration of treatment affects control of systemic inflammation and clinical improvement. Intensive Care Med 37:1153–1554
  35. Meduri GU (2007) There is no illumination in speculation. Additional data in support of methylprednisolone treatment in ARDS. Chest 132:1097–1100
    • View reference on publisher's website
  36. Thompson BT, Ancukiewicz M, Hudson LD, Steinberg KP, Bernard GR (2007) Steroid treatment for persistent ARDS: a word of caution. Crit Care 11:425
    • View reference on publisher's website
    • View reference on PubMed
  37. Marik PE, Pastores S, Annane D, Meduri G, Sprung C, Arlt W, Keh D, Briegel J, Beishuizen A, Dimopoulou I, Tsagarakis S, Singer M, Chrousos GP, Zaloga GP, Bokhari F, Vogeser M (2008) Clinical practice guidelines for the diagnosis and management of corticosteroid insufficiency in critical illness: recommendations of an international task force. Crit Care Med 36:1937–1949
    • View reference on publisher's website
    • View reference on PubMed
  38. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, Alexander PE, Fei Y, Vandvik PO, Loeb M, Guyatt GH (2015) Corticosteroid therapy for patients hospitalized with community-acquired Pneumonia: A systematic review and meta-analysis. Ann Intern Med 163(7):519–528
  39. Greos LS, Vichyanond P, Bloedow DC, Irvin CG, Larsen GL, Szefler SJ, Hill MR (1991) Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis. Am Rev Respir Dis 144:586–592
    • View reference on publisher's website
    • View reference on PubMed
  40. Jantz MA, Sahn SA (1999) Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med 160:1079–1100
    • View reference on publisher's website
    • View reference on PubMed
  41. Gupta L, James B (2012) Prone position and intravenous steroids for the management of severe ARDS. Thorax 67:A38
    • View reference on publisher's website
  42. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Guerin C, Prat G, Morange S, Roch A, Investigators AS (2010) Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 363:1107–1116
    • View reference on publisher's website
    • View reference on PubMed
  43. Dunser M, Hasibeder W, Rieger M, Mayr AJ (2004) Successful therapy of severe pneumonia-associated ARDS after pneumonectomy with ECMO and steroids. Ann Thorac Surg 78:335–337
    • View reference on publisher's website
    • View reference on PubMed
  44. Gomez Manjarres D, Gay E (2015) A promising combination for treating blastomyces induced ARDS. Am J Respir Crit Care Med 191:A1690

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement